Rezultati pretraživanja
  1. prije 8 sati

    What's the cost of selecting the right ? Make sure you are aware of all of the tests possible and contact us if you need help getting recommended CROs and !

  2. 3. velj

    Discover insider information from a recent roundtable discussion about the use of and what companies are looking for from them and much more. Download your copy here

  3. 3. velj

    Discover insider information from a recent roundtable discussion about the use of and what companies are looking for from them and much more. Download your copy here

  4. 31. sij

    ‘Lack of good CDMOs’ factor for Krystal’s $90m gene therapy plant via

  5. 30. sij

    Lack of good a factor for in investing $70-90m into internal PA gene therapy plant

  6. 15. sij

    Working with , and can reduce the overall cost and risk of a project. Find out more about the key trends and factors that are influencing companies to here:

  7. Sai Life Sciences, one of India's fastest growing Contract Development & Manufacturing Organizations (CDMOs)

  8. 13. pro 2019.

    🌲🎁 Our is to provide to different companies, from start-ups to large companies, as well as to other , to help their products to reach the market

  9. 27. stu 2019.

    Although pharmaceutical companies choose to for different reasons, many businesses work with CROs, CMOs and because it can reduce the overall cost and risk of their project. Explore the other factors driving a surge in outsourcing here:

  10. 19. stu 2019.

    "Outsourcing is a very effective way for pharma companies to tap into additional formulation expertise.” Our Global VP Innovator Products and Solutions, Nick Shackley, examines the growing partnership between and in :

  11. 4. stu 2019.
    Odgovor korisnicima

    Erin, based on review of 500+ 483s via FOI, Western finished dose have fewer observations on average than in-house facilities. Incomplete data to be sure, but your focus on CDMOs doesn’t fully align with the facts. Not speaking of 503B facilities though!

  12. On 12 November we organise with the workshop 'Technologies for improving bioavalilability of poorly water-soluble ' by Dr A. Loxley, consultant of (), one of the world's leading ▶️ Don't miss it! 👍

  13. 29. lis 2019.

    . interviewed Michel Lagarde, Executive VP of Thermo Fisher Scientific, about the challenges are facing as the pharma and markets rapidly grow.

  14. organises in collaboration with the workshop 'Technologies for improving bioavalilability of poorly water-soluble ', by Dr A. Loxley, consultant of (a company), one of the world's leading ▶️

  15. 23. lis 2019.

    Ready to use next-gen technology platforms and shift in portfolios from large volumes but simple, to lower volumes but complex or orphan molecules or even the lack of approved capacity for complex/sterile drugs are some reasons the have started to feel real +ve traction.

    Prikaži ovu nit
  16. 15. lis 2019.

    Pharma : long time veteran observer and good friend Jim Miller reflects on 20+ years’ learnings at

  17. In our current issue "Pharma & ", we have asked from the to describe their experiences and advice on the current market situation for and what trends are emerging in their project pipeline

  18. The continues to grow and is estimated at $1.5 trillion by 2021. An important driver is the trend to development and manufacturing to . We have asked executives working in this market to share their experiences.

  19. 26. ruj 2019.

    Supply chain digitization creates new revenue opportunities in the vaccine market via

  20. 24. ruj 2019.

    Biopharma Supply Chains At Industry 4.0 "To get to a full digital dialogue, drug sponsors and alike will need to muster their resources and usher in what the rest of the world already calls Industry 4.0."

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.